Loading company…
ID 400243036 · FY 2019–2024 · 6 years
კომპანიის ძირითად საქმიანობას წარმოადგენს ფარმაცევტული პროდუქციით საბითუმო ვაჭრობა.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|
| Total Revenue | 2,930 | 10,768 | 8,343 | 3,954 | 8,915 | 10,134 | +28.2% |
| Total COGS | -1,172 | -4,535 | -3,400 | -1,431 | -4,288 | -4,890 | +33.1% |
| Gross Profit | 1,757 | 6,233 | 4,943 | 2,524 | 4,627 | 5,243 | +24.4% |
| Gross Margin | 60.0% | 57.9% | 59.2% | 63.8% | 51.9% | 51.7% | |
| Total Operating Expenses | -378 | -1,481 | -1,816 | -1,238 | -369 | -1,029 | +22.2% |
| EBITDA | 1,380 | 4,751 | 3,127 | 1,285 | 4,258 | 4,215 | +25.0% |
| EBITDA Margin | 47.1% | 44.1% | 37.5% | 32.5% | 47.8% | 41.6% | |
| Total D&A | 0 | 0 | 0 | 0 | 0 | 0 | |
| EBIT / Operating Income | 1,380 | 4,751 | 3,127 | 1,285 | 4,258 | 4,215 | +25.0% |
| Total Other Income | 23 | 832 | -792 | -1,056 | 71 | -58 | nmf |
| Profit Before Tax | 1,402 | 5,583 | 2,336 | 229 | 4,329 | 4,157 | +24.3% |
| Total Income Tax | -11 | -42 | -9 | -22 | -17 | -11 | -0.1% |
| Net Profit / (Loss) | 1,391 | 5,541 | 2,327 | 208 | 4,312 | 4,146 | +24.4% |
| Net Margin | 47.5% | 51.5% | 27.9% | 5.2% | 48.4% | 40.9% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.